A Study of Mosliciguat in PH-ILD

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 135 participants.

Also called NCT06635850

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 135 participants (enrolled count) (from the registry)
Sponsor
Pulmovant, Inc. (from the registry)
Registry
  • NCT NCT06635850
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Japan, Latvia, Mexico, Netherlands, New Zealand, Poland, South Korea, Spain, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06635850. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-29 (actual); primary completion 2026-05-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Mosliciguat in PH-ILD
Acronym
PHocus
Condition
Interstitial Lung Disease
Condition
Lung Diseases
Condition
Vascular Diseases
Condition
Cardiovascular Diseases
Condition
Fibrosis
Intervention (Drug)
Mosliciguat
Intervention (Device)
Dry Powder Inhaler
Intervention (Drug)
Placebo
Lead sponsor
Pulmovant, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06635850
Content hash
602004adeb98a1fe007530e51413d42ca61f08535484f3614e3d927f0cd15c3d